<DOC>
	<DOCNO>NCT00385554</DOCNO>
	<brief_summary>This study test safety , side effect , acceptability two strengths UC-781 gel use woman men Botswana two week .</brief_summary>
	<brief_title>Botswana Study UC-781 Vaginal Microbicide</brief_title>
	<detailed_description>45 woman 45 men , healthy sexually active , 21-45 year old , without HIV infection , enrol Francistown Gaborone , Botswana . Volunteers randomize receive either 0.1 % 0.25 % UC-781 carbomer gel placebo gel ( 3 arm . Women instruct apply gel intravaginally , morning evening , prior sex ( always male condom use ) 14 consecutive day . Men instruct apply gel topically 14 consecutive night , bed , allow dry overnight , wash morning . Additionally instructed never use gel sex always use condom . Volunteers see weekly evaluation symptom , laboratory toxicity , genital exam finding ( colposcopy woman , plasma drug level . Acceptability assess focus group month complete gel use .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>2145 year old citizen Botswana willing use condom 14 day PAP smear ( normal , inflammation , ASCUS ) regular menses amenorrhea life within 1 hour study clinic pas comprehension test provide write informed consent genital mucosal disruption screen genital surgery within past 8 week pregnant within past 8 week currently breastfeed prior hysterectomy plan move within 2 month ALT , AST , total bilirubin , creatinine Grade 2 Prothrombin partial thromboplastin time Grade 2 In drug/vaccine safety trial Has one sexual partner past month Unwilling/unsure sex least twice weekly 2 week Any condition investigator believe interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>Botswana</keyword>
	<keyword>Preventing acquisition HIV infection</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>